Literature DB >> 17886288

Detection of Mycobacterium avium subspecies paratuberculosis from patients with Crohn's disease using nucleic acid-based techniques: a systematic review and meta-analysis.

I Abubakar1, D Myhill, S H Aliyu, P R Hunter.   

Abstract

This study is a systematic review and meta-analysis of studies using nucleic acid-based techniques to detect Mycobacterium avium paratuberculosis (MAP) in patients with Crohn's disease (CD) compared with controls. Database searches were conducted and risk difference estimates were calculated using meta-analysis. Fifty-eight studies were reviewed, 47 of which were included in the analysis. The pooled estimate of risk difference from all studies was 0.23 (95% confidence interval [CI], 0.14-0.32) using a random effects model. Similarly, MAP was detected more frequently from patients with CD compared with those with ulcerative colitis (risk difference 0.19, 95% CI, 0.10-0.28). Year of study, assay type, and inclusion of children explained some but not all of the observed heterogeneity. The data confirms the observation that MAP is detected more frequently among CD patients compared with controls. However, the pathogenic role of this bacterium in the gut remains uncertain. Our analysis demonstrates that there is an association between MAP and CD, across many sites, by many investigators, and controlling for a number of factors; however, this association remains controversial and inconclusive. Future studies should determine whether there is a pathogenic role.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17886288     DOI: 10.1002/ibd.20276

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  72 in total

Review 1.  IBD-what role do Proteobacteria play?

Authors:  Indrani Mukhopadhya; Richard Hansen; Emad M El-Omar; Georgina L Hold
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-02-21       Impact factor: 46.802

2.  Assessment of Dietzia subsp. C79793-74 for treatment of cattle with evidence of paratuberculosis.

Authors:  Robert E Click; Craig L Van Kampen
Journal:  Virulence       Date:  2010 May-Jun       Impact factor: 5.882

Review 3.  Mycobacterium paratuberculosis as a cause of Crohn's disease.

Authors:  Adrienne L McNees; Diane Markesich; Najah R Zayyani; David Y Graham
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2015-10-16       Impact factor: 3.869

Review 4.  Mycobacterium avium paratuberculosis and the etiology of Crohn's disease: a review of the controversy from the clinician's perspective.

Authors:  Greg Rosenfeld; Brian Bressler
Journal:  Can J Gastroenterol       Date:  2010-10       Impact factor: 3.522

Review 5.  Advances in epidemiology and diagnosis of inflammatory bowel diseases.

Authors:  Sobia Ali; Cyrus P Tamboli
Journal:  Curr Gastroenterol Rep       Date:  2008-12

6.  In the search of a cause of Crohn's disease.

Authors:  Govind K Makharia; Urvashi B Singh
Journal:  Indian J Gastroenterol       Date:  2009 Sep-Oct

Review 7.  Crohn's disease: evidence for involvement of unregulated transcytosis in disease etio-pathogenesis.

Authors:  Jay Pravda
Journal:  World J Gastroenterol       Date:  2011-03-21       Impact factor: 5.742

8.  Adherent-invasive Escherichia coli target the epithelial barrier.

Authors:  Eytan Wine; Juan C Ossa; Scott D Gray-Owen; Philip M Sherman
Journal:  Gut Microbes       Date:  2010-01-05

9.  Detection of Mycobacterium avium subspecies paratuberculosis in patients with Crohn's disease is unrelated to the presence of single nucleotide polymorphisms rs2241880 (ATG16L1) and rs10045431 (IL12B).

Authors:  James P Dalton; Alan Desmond; Fergus Shanahan; Colin Hill
Journal:  Med Microbiol Immunol       Date:  2014-02-13       Impact factor: 3.402

10.  Infliximab therapy increases the frequency of circulating CD16(+) monocytes and modifies macrophage cytokine response to bacterial infection.

Authors:  N Nazareth; F Magro; J Silva; M Duro; D Gracio; R Coelho; R Appelberg; G Macedo; A Sarmento
Journal:  Clin Exp Immunol       Date:  2014-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.